High Throughput Screening Assay for PARG Inhibitors
Montreal, September 18th, 2017 – BioAuxilium Research Inc. and the NEOMED Institute announced today the result of a successful collaboration whereby BioAuxilium has developed and validated for NEOMED a custom TR-FRET-based high-throughput screening (HTS) assay suitable for the discovery of poly (ADP-ribose) glycohydrolase (PARG) inhibitors.
“We are delighted by the outcome of our collaboration with BioAuxilium,” said Dr. Kemal Payza, Project Director at NEOMED and responsible for NEOMED’s PARG program. “This custom TR-FRET assay is robust and more sensitive than any other known assay to measure the activity of the PARG enzyme, and it will be a very valuable tool in screening libraries of molecules to identify PARG inhibitors,” he added.
“The development and validation of this TR-FRET PARG assay marks an important milestone in our collaborative partnership with NEOMED. This accomplishment further highlights our expertise in designing, developing and validating HTS-compatible assays,” stated Dr. Jaime Padros, President of BioAuxilium.
“The collaboration highlights what great things can be achieved in the ecosystem we have built within NEOMED. Now with 30 companies operating within our two R&D facilities, this is just one example of the type of partnerships we see being realized not only with NEOMED, but also among our resident companies; all in the effort to advance great science and potentially life saving medicines,” adds Donald Olds, President and CEO of the NEOMED Institute.
About TR-FRET assays
Time-resolved fluorescence resonance energy transfer (TR-FRET) assays detect the proximity of two fluorophores, a donor and an acceptor, when in close proximity. The TR-FRET assay for PARG measures the fluorescent signal emitted when the substrate for PARG is intact and is able to bind two fluorescent probes. When the PARG enzyme degrades the substrate, the two fluorescent probes can no longer bind close enough to emit a signal. Consequently, when PARG is active, there’s a loss of the TR-FRET signal over time. Compounds that inhibit PARG block the degradation of the substrate, so PARG inhibitors result in preservation of the TR-FRET signal.
Poly (ADP-ribose) glycohydrolase (PARG) is an enzyme that plays a key role in DNA damage repair and in the transformation of normal cells to cancer cells, promoting their growth and invasive capability. PARG is elevated in several cancers such as breast, lungs, prostate, and acute lymphoblastic leukemia. The inhibition of PARG aims to repress cancer growth and to sensitize cancer cells to DNA damage therapy.
BioAuxilium Research Inc. is a Canadian private biotechnology company specialized in the development and manufacturing of custom, ready-to-use TR-FRET assay kits that simplify assay workflow and accelerate drug discovery and life sciences research. The company was founded in 2013 by veteran scientists from PerkinElmer and is located at the NEOMED Institute. BioAuxilium kits are commercialized through strategic alliances with industrial partners. In addition to developing TR-FRET based assay kits, BioAuxilium provides customized services in assay development on a contract basis using a wide range of assay technologies. For more information, please visit our website: www.bioauxilium.com
About NEOMED Institute
NEOMED Institute is a not‐for‐profit organization whose mission is to bridge the gap between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with the creation of a vibrant and sustainable life science ecosystem. NEOMED operates two fully integrated research and development campuses in Montreal: one specializing in small molecule therapeutics, and the other specializing in the development of biologics and vaccines. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses (30 independent companies employing more than 300 people) and providing a dynamic environment that stimulates collaboration, innovation, and creativity. NEOMED’s wholly-owned for-profit subsidiary, NEOMED-LABS, a Contract Research Organization (CRO) providing customized and high-throughput immune-monitoring for clinical vaccine development, is one of these tenants. NEOMED is jointly funded by our pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website: www.neomed.ca
For more information, please contact:
BioAuxilium Research Inc.
Jaime Padrós, PhD, PMP
7171 Frederick-Banting, Suite 2115
Montreal, Quebec, CANADA H4S 1Z9
514-312-9033 Ext 101
President & CEO
Montreal, Quebec, H4S 1Z9, CANADA
514-367-1212 Ext. 206